Title : MAPK1E322K mutation increases head and neck squamous cell carcinoma sensitivity to erlotinib through enhanced secretion of amphiregulin.

Pub. Date : 2016 Apr 26

PMID : 27004400






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 MAPK1E322K mutation increases head and neck squamous cell carcinoma sensitivity to erlotinib through enhanced secretion of amphiregulin. Erlotinib Hydrochloride amphiregulin Homo sapiens
2 Knockdown of AREG in HNSCC cells harboring MAPK1E322K abrogated EGFR signaling and decreased sensitivity to erlotinib in vitro and in vivo. Erlotinib Hydrochloride amphiregulin Homo sapiens
3 These cumulative findings implicate increased AREG secretion and EGFR activation as contributing to increased erlotinib sensitivity in MAPK1E322K HNSCC. Erlotinib Hydrochloride amphiregulin Homo sapiens